改良补肾益气方(MBYF)作为福莫特罗和布地奈德附加治疗慢阻肺的有效性与安全性:多中心、双盲、安慰剂对照、平行组随机临床试验的研究方案:FB-MBYF试验
本研究为多中心、随机、双盲、安慰剂对照、平行组临床试验,拟纳入慢阻肺患者,按1:1随机接受360天安慰剂或改良补肾益气方(MBYF)作为布地奈德/福莫特罗的附加治疗,每2个月随访。主要结局为慢阻肺急性加重频率、次数和严重程度、CAT评分和肺功能检查,次要结局包括mMRC呼吸困难量表、6分钟步行试验、BODE指数、中医证候量化评分、炎症指标和下丘脑-垂体-肾上腺素轴功能,并检测基因型以探讨药物与疗效关系。
要点
- MBYF作为布地奈德/福莫特罗附加治疗,拟观察360天。
- 主要结局为AECOPD频率、次数、严重程度、CAT评分和肺功能。
- 将检测基因型以分析药物与疗效的关系。
核心结论
- 该研究方案旨在评估MBYF作为布地奈德/福莫特罗附加治疗在慢阻肺患者中的有效性与安全性,并确认影响疗效的相关基因。
研究设计与样本
- 多中心、随机、双盲、安慰剂对照、平行组临床试验,合格慢阻肺患者按1:1随机接受360天安慰剂或MBYF作为布地奈德/福莫特罗的附加治疗,每2个月随访。
主要发现
- 主要结局为AECOPD频率、次数和严重程度、CAT评分和肺功能检查。
- 次要结局包括mMRC呼吸困难量表、6分钟步行试验、BODE指数、中医证候量化评分、炎症指标和下丘脑-垂体-肾上腺素轴功能。
- 将检测基因型以确定药物与疗效之间的关系。
- 所有数据记录于病例报告表(CRF),采用SPSS V.20.0分析。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Inhaled glucocorticoid corticosteroid (ICS), long-acting β2-adrenoceptor agonist (LABA), and other drugs have limited therapeutic effects on COPD with significant individual differences. Traditional Chinese medicine (TCM)-modified Bushen Yiqi formula (MBYF) demonstrates advantages in COPD management in China. This study aims to evaluate the efficacy and safety of MBYF as an add-on to budesonide/formoterol in COPD patients and confirm the related genes affecting the therapeutic effect in the treatment of COPD. METHODS: In this multicentre, randomised, double-blind, placebo-controlled, parallel-group study, eligible patients with COPD will randomly receive a 360-day placebo or MBYF as an adjuvant to budesonide/formoterol in a 1:1 ratio and be followed up with every 2 months. The primary outcomes will be the frequency, times, and severity of acute exacerbation of COPD (AECOPD), COPD assessment test (CAT) score, and pulmonary function tests (PFTs). The secondary outcomes will include the modified Medical Research Council (mMRC) dyspnoea scale, 6-min walking test (6MWT), BODE index, quantitative scores of syndromes classified in TCM, inflammation indices, and hypothalamic-pituitary-adrenaline (HPA) axis function. We will also test the genotype to determine the relationship between drugs and efficacy. All the data will be recorded in case report forms (CRFs) and analysed by SPSS V.20.0. DISCUSSION: A randomized clinical trial design to evaluate the efficacy and safety of MBYF in COPD is described. The results will provide evidence for the combination therapy of modern medicine and TCM medicine, and individual therapy for COPD. TRIAL REGISTRATION: ID: ChiCTR1900026124 , Prospective registration.
引用
- Kong Q, Cao Y, Gao Z, et al. Efficacy and safety of modified Bushen Yiqi formulas (MBYF) as an add-on to formoterol and budesonide in the management of COPD: study protocol for a multicentre, double-blind, placebo-controlled, parallel-group, randomized clinical trial: FB-MBYF Trial. Trials. 2022. PMID: 35164853. doi:10.1186/s13063-022-06057-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。